Replies to post #105526 on Biotech Values

[jbog]

Vinmantoo,,,,

I wouldn't be too worried about the options because they don't seem to be pushed up by any great amount. There is a scary amount of volume.

I think that once Momenta's financials come out we'll finally have all the answers that are causing a great deal of confusion. The only question that'll be left is Teva.

[vinmantoo]

MNTA drop is par for Wall Street. A posted a week ago


<<Based on the way Wall Street works, I expect MNTA will be driven down a bit more during October into the $13s/share range, then surge at the end of the month when m-enoxaparin sales figures are released. This will soon be followed by one or more analysts saying they have good information that Teva will soon have their version of Lovenox approved, which will drive MNTA price down again. Of course MNTA will keep accumulating cash but the cycle will repeat in the next quarter with difference being that the baseline MNTA price will be higher. >>


After the earnings report comes out MNTA will be higher than it was before the Wall Street games, but the big boys have to make sure their clients make the money possible.